Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.
 
> α-Terpineol [98-55-5]

α-Terpineol [98-55-5]

Imprimer Imprimer
Identifiez-vous
Commande minimum 2

Référence HY-N5142-1mL

Conditionnement : 10mM/1mL

Marque : MedChemExpress


Description

α-Terpineol (with oral activity) can be found in Eucalyptus globulus Labill. α-Terpineol exhibits strong antimicrobial activity against periodontopathic and cariogenic bacteria.α-Terpineol possesses antifungal activity against T. mentagrophytes, and the activity might lead to irreversible cellular disruption. In addition, α-Terpineol exhibits antineuropathic and anti-inflammatory activities. α-Terpineol can be utilized in research related to diarrhea, neuropathic pain, infections, and inflammation[1][2][3][4][5][6][7].

In Vitro

α-Terpineol (1-10 µM, 20 h) exerts anti-inflammatory effects in LPS-stimulated mouse peritoneal macrophages by inhibiting the NF-κB signaling pathway[4].
α-Terpineol (0.06-0.125% v/v, 48 h) inhibits the growth of G. vaginalis (MIC = 0.06%) and C. albicans (MIC = 0.125%), showing antimicrobial activity comparable to Clotrimazole (HY-10882) ((v/v) represents volume/volume concentration, indicating the proportion of α-Terpineol in the culture medium)[4].
α-Terpineol (1-100 μM, 24 h) inhibits AMPK phosphorylation, activates SREBP-1, and promotes lipid synthesis in HepG2 cells[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

α-Terpineol Related Antibodies

Western Blot Analysis[7]

Cell Line: HepG2 cells (hepatocellular carcinoma)
Concentration: 1, 10, 100 μM
Incubation Time: 24 h
Result: Inhibited AMPK phosphorylation, promoted p70S6K phosphorylation, and increased SREBP-1 maturation.

Real Time qPCR[7]

Cell Line: HepG2 cells (hepatocellular carcinoma)
Concentration: 1, 10, 100 μM
Incubation Time: 24 h
Result: Upregulated lipid synthesis-related genes Srebf-1c, Acc, Fasn, Scd-1.
In Vivo

α-Terpineol (6.25-50 mg/kg, p.o., single administration) exhibits antidiarrheal activity by exerting anticholinergic effects, blocking PGE2 and GM1 receptors, and interacting with cholera toxin, thereby reducing castor oil-induced diarrhea in a mouse model of acute diarrhea[5].
\ α-Terpineol (56 mg/kg, i.p., single administration) provides short-term relief of mechanical pain in a mouse model of neuropathic pain induced by chronic constriction injury[6].
α-Terpineol (100 mg/kg and 500 mg/kg, p.o., once daily for 2 weeks) induces fatty liver and promoted hepatic lipid accumulation in C57BL/6 mice[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Castor oil-induced acute diarrhea Swiss mouse model[5]
Dosage: 6.25, 12.5, 25, 50 mg/kg
Administration: Oral gavage (p.o.), single dose
Result: Significantly reduced total stool amount (55%, 48%, 44%, 24%) and diarrhea rate (47%, 66%; 56%, 10%). All doses significantly decreased castor oil-induced enteropooling (46%, 78%, 66%, 41%)
Animal Model: Neuropathic pain C57BL/6 mouse model induced by Chronic Constriction Injury[6]
Dosage: 56 mg/kg
Administration: ntraperitoneal injection (i.p.), single dose
Result: Complete reversal of mechanical allodynia at 30 min, returning to baseline at 2 h, partial reversal at 3 h, no significant effect at 6 h.
Animal Model: C57BL/6 mice[7]
Dosage: 100 mg/kg and 500 mg/kg
Administration: Oral gavage (p.o.), once daily, for 2 weeks
Result: Increased hepatic triglyceride (TG) levels by 2-fold and serum TG levels by 25% (500 mg/kg);
Induced microvesicular steatosis in the liver, and enhanced neutral lipid accumulation as revealed by Oil Red O staining.
Masse moléculaire

154.25

Formule

C10H18O
CAS No.
Appearance

<31°C Solid,>35°C Liquid

Color

Colorless to off-white

SMILES

OC(C)(C)C1CC=C(C)CC1
Structure Classification
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage
Pure form -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
Solvant et solubilité
In Vitro: 

DMSO : 200 mg/mL (1296.60 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 6.4830 mL 32.4149 mL 64.8298 mL
5 mM 1.2966 mL 6.4830 mL 12.9660 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 5 mg/mL (32.41 mM); Clear solution

    This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 5 mg/mL (32.41 mM); Clear solution

    This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Pureté et documentation
Références